Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-expand-ipsc-collaboration-to-include-additional-cell-lines-5733